Research Article
Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation
Figure 1
FOXO3A contributes to DAC-induced SKM-1 cell differentiation. (a, b) CD14 (marker for monocytes), but not CD11b (marker for myeloid cells), was significantly induced in SKM-1 cells treated with 0.5 μM DAC for 3 and 6 days. (c) Western blot showed that DAC treatment increases FOXO3A expression and FOXO3A/p-FOXO3A ratio. (d) Western blot showed that siRNA targeting FOXO3A decreased FOXO3A expression about 70% compared to negative control siRNA. (e) Surface CD14 and CD11b expression had clearly no change between FOXO3A siRNA and negative control siRNA in SKM-1 cells. (f) Western blot showed that FOXO3A siRNA could decrease FOXO3A expression in DAC-treated SKM-1 cells. (g) Surface CD14 expression was impaired by about 50% in FOXO3A siRNA compared with negative control siRNA in DAC-treated SKM-1 cells. Two tailed .
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |